✦ LIBER ✦

Risedronate treatment of postmenopausal women with low bone mass: Preliminary data

✍ Scribed by M. McClung; W. Bensen; M. Bolognese; S. Bonnick; M. Ettinger; S. Harris; H. Heath; R. Lang; P. Miller; E. Pavlov; S. Silverman; G. Woodson; K. Faulkner; P. Bekker

Publisher: Springer-Verlag
Year: 1996
Tongue: English
Weight: 134 KB
Volume: 6
Category: Article
ISSN: 0937-941X
DOI: 10.1007/bf02500566

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effect of chronic treatment with iprifla

Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass

✍ C. Gennan 📂 Article 📅 1996 🏛 Springer-Verlag 🌐 English ⚖ 99 KB

Effect of chronic treatment with iprifla

Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass

✍ C. Gennari; S. Adami; D. Agnusdei; L. Bufalino; R. Cervetti; G. Crepaldi; C. Di 📂 Article 📅 1997 🏛 Springer 🌐 English ⚖ 486 KB

Evidence that Treatment with Risedronate

Evidence that Treatment with Risedronate in Women with Postmenopausal Osteoporosis Affects Bone Mineralization and Bone Volume

✍ Peter Fratzl; Paul Roschger; Nadja Fratzl-Zelman; Eleftherios P. Paschalis; Roge 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 240 KB

Effects of 1-year treatment with iprifla

Effects of 1-year treatment with ipriflavone on bone in postmenopausal women with low bone mass

✍ M. Valente; L. Bufalino; G. N. Castiglione; R. D'Angelo; A. Mancuso; P. Galoppi; 📂 Article 📅 1994 🏛 Springer 🌐 English ⚖ 368 KB

Seven Years of Treatment with Risedronat

Seven Years of Treatment with Risedronate in Women with Postmenopausal Osteoporosis

✍ D. D. Mellström; O. H. Sörensen; S. Goemaere; C. Roux; T. D. Johnson; A. A. Chin 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 186 KB

Seven Years of Treatment with Risedronat

Seven Years of Treatment with Risedronate in Women with Postmenopausal Osteoporosis

✍ D. D. Mellström; O. H. Sörensen; S. Goemaere; C. Roux; T. D. Johnson; A. A. Chin 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 186 KB

The effects of 7 years of risedronate treatment were evaluated in a second 2-year extension of a 3-year vertebral fracture study in women with osteoporosis. For the first 5 years of the study, women received risedronate 5 mg/day or placebo according to the original randomization, with maintenance of